Immunology of cryptococcal infections: Developing a rational approach to patient therapy

Waleed Elsegeiny, Kieren Marr, Peter R. Williamson

Research output: Contribution to journalShort survey

Abstract

Cryptococcal meningoencephalitis is responsible for upwards of 15% of HIV-related deaths worldwide and is currently the most common cause of non-viral meningitis in the US, affecting both previously healthy and people with immune suppression caused by cancer chemotherapy, transplantation, and biologic therapies. Despite a continued 30-50% attributable mortality, recommended therapeutic strategies have remained largely unchanged since the 1950s. Recent murine models and human studies examining the role of the immune system in both susceptibility to the infection as well as host damage have begun to influence patient care decisions. The Damage Framework Response, originally proposed in 1999, was recently used to discuss dichotomous etiologies of host damage in cryptococcal disease. These include patients suffering microbiological damage with low host immunity (especially those immunosuppressed with HIV) and those having low (live) microbiological burden but high immune-mediated damage (HIV-related immune reconstitution syndrome and non-HIV-related postinfectious inflammatory response syndrome). Cryptococcal disease in previously healthy hosts, albeit rare, has been known for a long time. Immunophenotyping and dendritic cell-T cell signaling studies on cerebral spinal fluid of these rare patients reveal immune capacity for recognition and T-cell activation pathways including increased levels of HLA-DR and CD56. However, despite effective T-cell signals, brain biopsy and autopsy specimens demonstrated an M2 alternative macrophage polarization and poor phagocytosis of fungal cells. These studies expand the paradigm for cryptococcal disease susceptibility to include a prominent role for immune-mediated damage and suggest a need for careful individual consideration of immune activation during therapy of cryptococcal disease in diverse hosts.

Original languageEnglish (US)
Article number651
JournalFrontiers in Immunology
Volume9
Issue numberAPR
DOIs
StatePublished - Apr 4 2018

Fingerprint

Allergy and Immunology
HIV
T-Lymphocytes
Infection
Immune Reconstitution Inflammatory Syndrome
Cytophagocytosis
Immunophenotyping
Biological Therapy
Meningoencephalitis
Disease Susceptibility
HLA-DR Antigens
Meningitis
Dendritic Cells
Autopsy
Immune System
Immunity
Patient Care
Therapeutics
Transplantation
Macrophages

Keywords

  • Cryptococcal
  • Cryptococcus
  • Fungus
  • Infection
  • Meningitis
  • Meningoencephalitis
  • Neurology

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Immunology of cryptococcal infections : Developing a rational approach to patient therapy. / Elsegeiny, Waleed; Marr, Kieren; Williamson, Peter R.

In: Frontiers in Immunology, Vol. 9, No. APR, 651, 04.04.2018.

Research output: Contribution to journalShort survey

@article{66d9a1d75c324504ab5b0eca34056a9e,
title = "Immunology of cryptococcal infections: Developing a rational approach to patient therapy",
abstract = "Cryptococcal meningoencephalitis is responsible for upwards of 15{\%} of HIV-related deaths worldwide and is currently the most common cause of non-viral meningitis in the US, affecting both previously healthy and people with immune suppression caused by cancer chemotherapy, transplantation, and biologic therapies. Despite a continued 30-50{\%} attributable mortality, recommended therapeutic strategies have remained largely unchanged since the 1950s. Recent murine models and human studies examining the role of the immune system in both susceptibility to the infection as well as host damage have begun to influence patient care decisions. The Damage Framework Response, originally proposed in 1999, was recently used to discuss dichotomous etiologies of host damage in cryptococcal disease. These include patients suffering microbiological damage with low host immunity (especially those immunosuppressed with HIV) and those having low (live) microbiological burden but high immune-mediated damage (HIV-related immune reconstitution syndrome and non-HIV-related postinfectious inflammatory response syndrome). Cryptococcal disease in previously healthy hosts, albeit rare, has been known for a long time. Immunophenotyping and dendritic cell-T cell signaling studies on cerebral spinal fluid of these rare patients reveal immune capacity for recognition and T-cell activation pathways including increased levels of HLA-DR and CD56. However, despite effective T-cell signals, brain biopsy and autopsy specimens demonstrated an M2 alternative macrophage polarization and poor phagocytosis of fungal cells. These studies expand the paradigm for cryptococcal disease susceptibility to include a prominent role for immune-mediated damage and suggest a need for careful individual consideration of immune activation during therapy of cryptococcal disease in diverse hosts.",
keywords = "Cryptococcal, Cryptococcus, Fungus, Infection, Meningitis, Meningoencephalitis, Neurology",
author = "Waleed Elsegeiny and Kieren Marr and Williamson, {Peter R.}",
year = "2018",
month = "4",
day = "4",
doi = "10.3389/fimmu.2018.00651",
language = "English (US)",
volume = "9",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "APR",

}

TY - JOUR

T1 - Immunology of cryptococcal infections

T2 - Developing a rational approach to patient therapy

AU - Elsegeiny, Waleed

AU - Marr, Kieren

AU - Williamson, Peter R.

PY - 2018/4/4

Y1 - 2018/4/4

N2 - Cryptococcal meningoencephalitis is responsible for upwards of 15% of HIV-related deaths worldwide and is currently the most common cause of non-viral meningitis in the US, affecting both previously healthy and people with immune suppression caused by cancer chemotherapy, transplantation, and biologic therapies. Despite a continued 30-50% attributable mortality, recommended therapeutic strategies have remained largely unchanged since the 1950s. Recent murine models and human studies examining the role of the immune system in both susceptibility to the infection as well as host damage have begun to influence patient care decisions. The Damage Framework Response, originally proposed in 1999, was recently used to discuss dichotomous etiologies of host damage in cryptococcal disease. These include patients suffering microbiological damage with low host immunity (especially those immunosuppressed with HIV) and those having low (live) microbiological burden but high immune-mediated damage (HIV-related immune reconstitution syndrome and non-HIV-related postinfectious inflammatory response syndrome). Cryptococcal disease in previously healthy hosts, albeit rare, has been known for a long time. Immunophenotyping and dendritic cell-T cell signaling studies on cerebral spinal fluid of these rare patients reveal immune capacity for recognition and T-cell activation pathways including increased levels of HLA-DR and CD56. However, despite effective T-cell signals, brain biopsy and autopsy specimens demonstrated an M2 alternative macrophage polarization and poor phagocytosis of fungal cells. These studies expand the paradigm for cryptococcal disease susceptibility to include a prominent role for immune-mediated damage and suggest a need for careful individual consideration of immune activation during therapy of cryptococcal disease in diverse hosts.

AB - Cryptococcal meningoencephalitis is responsible for upwards of 15% of HIV-related deaths worldwide and is currently the most common cause of non-viral meningitis in the US, affecting both previously healthy and people with immune suppression caused by cancer chemotherapy, transplantation, and biologic therapies. Despite a continued 30-50% attributable mortality, recommended therapeutic strategies have remained largely unchanged since the 1950s. Recent murine models and human studies examining the role of the immune system in both susceptibility to the infection as well as host damage have begun to influence patient care decisions. The Damage Framework Response, originally proposed in 1999, was recently used to discuss dichotomous etiologies of host damage in cryptococcal disease. These include patients suffering microbiological damage with low host immunity (especially those immunosuppressed with HIV) and those having low (live) microbiological burden but high immune-mediated damage (HIV-related immune reconstitution syndrome and non-HIV-related postinfectious inflammatory response syndrome). Cryptococcal disease in previously healthy hosts, albeit rare, has been known for a long time. Immunophenotyping and dendritic cell-T cell signaling studies on cerebral spinal fluid of these rare patients reveal immune capacity for recognition and T-cell activation pathways including increased levels of HLA-DR and CD56. However, despite effective T-cell signals, brain biopsy and autopsy specimens demonstrated an M2 alternative macrophage polarization and poor phagocytosis of fungal cells. These studies expand the paradigm for cryptococcal disease susceptibility to include a prominent role for immune-mediated damage and suggest a need for careful individual consideration of immune activation during therapy of cryptococcal disease in diverse hosts.

KW - Cryptococcal

KW - Cryptococcus

KW - Fungus

KW - Infection

KW - Meningitis

KW - Meningoencephalitis

KW - Neurology

UR - http://www.scopus.com/inward/record.url?scp=85044986715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044986715&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2018.00651

DO - 10.3389/fimmu.2018.00651

M3 - Short survey

C2 - 29670625

AN - SCOPUS:85044986715

VL - 9

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - APR

M1 - 651

ER -